Perspectives of People with HCV Lived Experience and Healthcare Providers on Potential Long-Acting Therapies

Treatment Action Group (TAG) released an advocacy brief discussing findings from two surveys conducted among end users and healthcare providers/policy makers to understand their perspectives on, and the facilitators and barriers to potential long-acting therapies for hepatitis C virus (HCV) cure currently being developed by the LONGEVITY consortium, funded by the global health agency Unitaid. These survey results have been published in scientific peer review journals with open access (here and here).

To ensure broader access to these survey findings and promote broader engagement between scientific researchers, policy makers and community members who are the end users of long-acting therapies, in this advocacy brief TAG breaks down and summarizes the survey results for an easier read, and equally discusses some of the major barriers to HCV care in low- and middle-income countries, and how these barriers can be addressed to pave the way for global equitable access to a potential single shot long-acting HCV injectable cure.

Access the advocacy brief here.

Source: TAG